FDA Says Final CLIA Waiver Guidance Eases Burdens; Industry Isn’t Satisfied
This article was originally published in The Gray Sheet
Executive Summary
Final guidelines to companies developing point-of-care diagnostic tests for use in less sophisticated laboratories offer more leeway in clinical trial design than FDA initially proposed